Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven C Clifford

Showing results (41-50 of 123) with videos related to

Pageof 13
Sort By:
Brain Pathology (Zurich, Switzerland)|March 29, 2007
Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behaviorCharles S McManamy, Jane Pears, Claire L Weston, et al.
Scientific Reports|January 12, 2020
The AHR pathway represses TGFβ-SMAD3 signalling and has a potent tumour suppressive role in SHH medulloblastomaNemanja Sarić, Matthew Selby, Vijay Ramaswamy, et al.
The Lancet. Oncology|November 6, 2018
Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trialTobias Goschzik, Edward C Schwalbe, Debbie Hicks, et al.
Neuro-Oncology Advances|July 1, 2024
In vivo modeling recapitulates radiotherapy delivery and late-effect profile for childhood medulloblastomaJemma Castle, Gary Shaw, Dominic Weller, et al.
BMJ Open|June 3, 2021
Acceptance and commitment therapy for young brain tumour survivors: study protocol for an acceptability and feasibility trialSam Malins, Ray Owen, Ingram Wright, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variablesDavid W Ellison, Mehmet Kocak, James Dalton, et al.
Nature Communications|April 2, 2025
Structural mimicry of UM171 and neomorphic cancer mutants co-opts E3 ligase KBTBD4 for HDAC1/2 recruitmentZhuoyao Chen, Gamma Chi, Timea Balo, et al.
Cancer Research|July 5, 2002
Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau diseaseMalgorzata Zatyka, Nancy Fernandes da Silva, Steven C Clifford, et al.
Cell Death and Differentiation|April 5, 2022
Disease-associated KBTBD4 mutations in medulloblastoma elicit neomorphic ubiquitylation activity to promote CoREST degradationZhuoyao Chen, Rafael M Ioris, Stacey Richardson, et al.
JCO Global Oncology|October 17, 2022
How Can Genomic Innovations in Pediatric Brain Tumors Transform Outcomes in Low- and Middle-Income Countries?Simon Bailey, Alan Davidson, Jeannette Parkes, et al.
Pageof 13

Showing results (41-50 of 123) with videos related to

Sort By:
Pageof 13
Brain Pathology (Zurich, Switzerland)|March 29, 2007
Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behaviorCharles S McManamy, Jane Pears, Claire L Weston, et al.
Scientific Reports|January 12, 2020
The AHR pathway represses TGFβ-SMAD3 signalling and has a potent tumour suppressive role in SHH medulloblastomaNemanja Sarić, Matthew Selby, Vijay Ramaswamy, et al.
The Lancet. Oncology|November 6, 2018
Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trialTobias Goschzik, Edward C Schwalbe, Debbie Hicks, et al.
Neuro-Oncology Advances|July 1, 2024
In vivo modeling recapitulates radiotherapy delivery and late-effect profile for childhood medulloblastomaJemma Castle, Gary Shaw, Dominic Weller, et al.
BMJ Open|June 3, 2021
Acceptance and commitment therapy for young brain tumour survivors: study protocol for an acceptability and feasibility trialSam Malins, Ray Owen, Ingram Wright, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variablesDavid W Ellison, Mehmet Kocak, James Dalton, et al.
Nature Communications|April 2, 2025
Structural mimicry of UM171 and neomorphic cancer mutants co-opts E3 ligase KBTBD4 for HDAC1/2 recruitmentZhuoyao Chen, Gamma Chi, Timea Balo, et al.
Cancer Research|July 5, 2002
Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau diseaseMalgorzata Zatyka, Nancy Fernandes da Silva, Steven C Clifford, et al.
Cell Death and Differentiation|April 5, 2022
Disease-associated KBTBD4 mutations in medulloblastoma elicit neomorphic ubiquitylation activity to promote CoREST degradationZhuoyao Chen, Rafael M Ioris, Stacey Richardson, et al.
JCO Global Oncology|October 17, 2022
How Can Genomic Innovations in Pediatric Brain Tumors Transform Outcomes in Low- and Middle-Income Countries?Simon Bailey, Alan Davidson, Jeannette Parkes, et al.
Pageof 13